A Phase 2 interventional study of Midomafetamine HCl and Placebo in Anxiety, sponsored by Lykos Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.
Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with anxiety associated with a life-threatening illness. The main question it aims to answer is: Does anxiety decrease in people receiving two sessions of MDMA-assisted therapy?
Researchers will compare people receiving placebo with therapy to people receiving MDMA-assisted therapy.
This Phase 2 pilot study is a randomized, double-blind, placebo-controlled study in 18 participants comparing the effects of MDMA-assisted therapy vs. placebo with therapy. Thirteen participants were randomized to the active dose condition of 125 mg of MDMA HCl (plus an optional supplemental dose of 62.5 mg MDMA HCl) with therapy and five participants were randomized to the placebo with therapy condition. The study consisted of two blinded experimental sessions of MDMA-assisted therapy or placebo with therapy, each session lasting six to eight hours and scheduled two to four weeks apart. Each participant was unblinded one month after their second experimental session in Stage 1. After unblinding, participants receiving MDMA were to complete a third open-label experimental session of MDMA-assisted therapy and participants who originally received placebo had the opportunity to cross over to open-label Stage 2 and receive active MDMA-assisted therapy in 3 sessions.
The primary objective of the study is to assess changes in trait anxiety in subjects receiving active dose MDMA compared to those receiving placebo as measured by State-Trait Anxiety Index (STAI) Trait scores from Baseline to the Primary Endpoint (one month after the second experimental session).
7,231 studies on the registry are indexed under Anxiety Disorders; 1,686 are open to participants now.
This study's enrollment of 18 is below the median of 80 across 6,085 interventional studies indexed under Anxiety Disorders.
Browse Anxiety Disorders studies →Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inactive placebo administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by (optional) inactive placebo supplemental dose.
Drug: Placebo · Behavioral: Therapy
125 mg midomafetamine HCl administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by a (optional) supplemental dose of 62.5 mg.
Drug: Midomafetamine HCl · Behavioral: Therapy
Two sessions of MDMA-assisted therapy lasting six to eight hours, scheduled two to four weeks apart.
Also known as: 3,4-methylenedioxymethamphetamine, Midomafetamine, MDMA
Two sessions of placebo with therapy lasting six to eight hours, scheduled two to four weeks apart.
Also known as: Inactive placebo
Manualized therapy
Change in State Trait Anxiety Inventory (STAI) Trait Score From Baseline to Primary Endpoint
The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80. The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure was intended to target those anxiety symptoms that are chronic and pervasive.
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Primary Endpoint STAI Trait Score
The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80. The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive.
Time frame: One month post-2nd experimental session
Change in STAI State Score From Baseline to Primary Endpoint
The state subscale of the STAI (STAI-S) is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Like the trait subscale, participants respond to each item on the state subscale by selecting a response from a 4-point Likert scale ranging from 4 ("Not at all") to 1 ("Very much so"), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80. The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive.
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Beck Depression Inventory-II (BDI-II) Score From Baseline to Primary Endpoint
The Beck Depression Inventory-II (BDI-II) is a a 21-item self-reported measure of depression according to Diagnostic and Statistical Manual IV (DSM-IV) criteria. Each item is rated on a 4-point Likert scale ranging from 0 to 3. The total score is the sum of 21 items and range from 0 to 63. Score cutoffs indicate: 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, and 29-63 severe depression. Higher scores indicate more severe depressive symptoms.
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint
The Global Assessment of Function (GAF) is a measure of a person's global social functioning made through clinical observation. The GAF consists of a single score, with scores ranging from 0 to 100, with 100 reflecting superior function and zero reflecting serious risk of causing harm to the self or others.
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post 2nd experimental session)
Change in MADRS Score From Baseline to Primary Endpoint
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item, clinician administered questionnaire used to diagnose the severity of depressive episodes. Each item has a score of 0 to 6. Overall scores are summed and range from 0 to 60. Score cutoffs indicate: 0-6 normal/symptom absent, 7-19 mild depression, 20-34 moderate depression, \> 34 severe depression. Higher scores indicate greater severe depression.
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Pittsburgh Sleep Quality Inventory (PSQI) From Baseline to Primary Endpoint
The Pittsburgh Sleep Quality Index (PSQI) is a measure of self-reported sleep quality over a one month period. It consists of 19 items with possible responses ranging from zero to four on a five-point scale. The PSQI consists of seven sub-scales: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medications, and daytime dysfunction. These are all summed to produce a single global scale. Global scores can range from 0 to 21, with higher scores reflecting poorer sleep quality, and a score below 5 indicating good sleep quality.
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint
The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales; relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Questions are answered on a scale from 0 (I did not experience this change) to 5 (I experienced this change to a great degree). Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth.
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Functional Assessment of Chronic Illness Therapy Scale (FACIT) From Baseline to Primary Endpoint
The Functional Assessment of Chronic Illness Therapy Scale (FACIT-Sp) is a 27-item self-report measure of quality of life issues specifically relevant to individuals with a chronic or life-threatening illness or condition. The core questionnaire consists of four subscales: Physical Well-being, Social/Family Well-being, Emotional Well-being, and Functional Well-being. Responses range from 0 (not at all) to 4 (very much), with higher scores indicating greater well-being. For each subscale, total scores were summed and range from 0 to 16.
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Death Attitudes Profile (DAP) From Baseline to Primary Endpoint
The Death Attitudes Profile (DAP) is a 32-item self-reported questionnaire that assesses individual attitudes and beliefs about death and dying. Each item on the scale is rated along a 7-point Likert scale ranging from "strongly disagree" (score of 1) to "strongly agree" (score of 7), with higher scores indicating more positive attitudes toward death. The DAP consists of 5 dimensions: fear of death (7 items summed with total scores ranging from 7 to 49), death avoidance (5 items summed with total scores ranging from 5 to 35), neutral acceptance (5 items summed with total scores ranging from 5 to 35), approach acceptance (10 items summed with total scores ranging from 10 to 70), and escape acceptance (5 items summed with total scores ranging from 5 to 35). For each dimension, a mean scale score can be computed by dividing the total scale score by the number of items forming each scale.
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Change in Self-Compassion Scale (SCS) From Baseline to Primary Endpoint
The Self-Compassion Scale (SCS) is a 26-item self-reported questionnaire that assesses how respondents relate to themselves and treat themselves during difficult or painful experiences. Items are scored along a 5-point Likert-type scale ranging from 1 "almost never" to 5 "almost always." The SCS has six component (subscale) scores: self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification. Subscale scores are calculated by computing the mean of subscale item responses. A total self-compassion score is calculated by the sum of the subscale scores and range from 24 to 120 with higher scores indicating greater self compassion. Higher scores have been found to correlate with positive mental health outcomes, as well as decreased depression and anxiety.
Time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)
Participants were recruited through printed ads, internet ads, referrals from other psychiatrists, psychotherapists or physicians, and through word of mouth.
| Milestone | Placebo With Therapy | MDMA-assisted Therapy (125 mg) |
|---|---|---|
| Started | 5 | 13 |
| Completed | 5 | 13 |
| Not completed | 0 | 0 |
The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80. The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure was intended to target those anxiety symptoms that are chronic and pervasive.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy (125 mg) |
|---|---|---|
| Change in State Trait Anxiety Inventory (STAI) Trait Score From Baseline to Primary Endpoint | -8.8 ± 14.7 | -23.5 ± 13.2 |
The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80. The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy (125 mg) |
|---|---|---|
| Primary Endpoint STAI Trait Score | 48.6 ± 12.6 | 38.9 ± 10.6 |
The state subscale of the STAI (STAI-S) is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Like the trait subscale, participants respond to each item on the state subscale by selecting a response from a 4-point Likert scale ranging from 4 ("Not at all") to 1 ("Very much so"), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80. The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy (125 mg) |
|---|---|---|
| Change in STAI State Score From Baseline to Primary Endpoint | -6.0 ± 15.8 | -22.1 ± 17.9 |
The Beck Depression Inventory-II (BDI-II) is a a 21-item self-reported measure of depression according to Diagnostic and Statistical Manual IV (DSM-IV) criteria. Each item is rated on a 4-point Likert scale ranging from 0 to 3. The total score is the sum of 21 items and range from 0 to 63. Score cutoffs indicate: 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, and 29-63 severe depression. Higher scores indicate more severe depressive symptoms.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy (125 mg) |
|---|---|---|
| Change in Beck Depression Inventory-II (BDI-II) Score From Baseline to Primary Endpoint | -14.6 ± 8.6 | -20.9 ± 13.8 |
The Global Assessment of Function (GAF) is a measure of a person's global social functioning made through clinical observation. The GAF consists of a single score, with scores ranging from 0 to 100, with 100 reflecting superior function and zero reflecting serious risk of causing harm to the self or others.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy (125 mg) |
|---|---|---|
| Change in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint | 3.0 ± 12.5 | 6.6 ± 9.7 |
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item, clinician administered questionnaire used to diagnose the severity of depressive episodes. Each item has a score of 0 to 6. Overall scores are summed and range from 0 to 60. Score cutoffs indicate: 0-6 normal/symptom absent, 7-19 mild depression, 20-34 moderate depression, \> 34 severe depression. Higher scores indicate greater severe depression.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy (125 mg) |
|---|---|---|
| Change in MADRS Score From Baseline to Primary Endpoint | -7.0 ± 7.2 | -10.5 ± 8.2 |
The Pittsburgh Sleep Quality Index (PSQI) is a measure of self-reported sleep quality over a one month period. It consists of 19 items with possible responses ranging from zero to four on a five-point scale. The PSQI consists of seven sub-scales: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medications, and daytime dysfunction. These are all summed to produce a single global scale. Global scores can range from 0 to 21, with higher scores reflecting poorer sleep quality, and a score below 5 indicating good sleep quality.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy (125 mg) |
|---|---|---|
| Change in Pittsburgh Sleep Quality Inventory (PSQI) From Baseline to Primary Endpoint | -0.2 ± 1.3 | -3.6 ± 5.4 |
The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales; relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Questions are answered on a scale from 0 (I did not experience this change) to 5 (I experienced this change to a great degree). Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy (125 mg) |
|---|---|---|
| Change in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint | -2.6 ± 6.1 | 12.9 ± 23.2 |
The Functional Assessment of Chronic Illness Therapy Scale (FACIT-Sp) is a 27-item self-report measure of quality of life issues specifically relevant to individuals with a chronic or life-threatening illness or condition. The core questionnaire consists of four subscales: Physical Well-being, Social/Family Well-being, Emotional Well-being, and Functional Well-being. Responses range from 0 (not at all) to 4 (very much), with higher scores indicating greater well-being. For each subscale, total scores were summed and range from 0 to 16.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy (125 mg) |
|---|---|---|
| Physical well-being | 2.8 ± 5.0 | 1.4 ± 4.4 |
| Social/ family well-being | -2.0 ± 2.9 | 0.8 ± 3.4 |
| Emotional well-being | 1.0 ± 2.2 | 1.6 ± 7.1 |
| Functional well-being | 1.0 ± 1.6 | 4.8 ± 5.8 |
| Additional concerns | -0.3 ± 5.0 | 4.5 ± 11.9 |
The Death Attitudes Profile (DAP) is a 32-item self-reported questionnaire that assesses individual attitudes and beliefs about death and dying. Each item on the scale is rated along a 7-point Likert scale ranging from "strongly disagree" (score of 1) to "strongly agree" (score of 7), with higher scores indicating more positive attitudes toward death. The DAP consists of 5 dimensions: fear of death (7 items summed with total scores ranging from 7 to 49), death avoidance (5 items summed with total scores ranging from 5 to 35), neutral acceptance (5 items summed with total scores ranging from 5 to 35), approach acceptance (10 items summed with total scores ranging from 10 to 70), and escape acceptance (5 items summed with total scores ranging from 5 to 35). For each dimension, a mean scale score can be computed by dividing the total scale score by the number of items forming each scale.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy (125 mg) |
|---|---|---|
| Fear of death | -0.6 ± 1.0 | -0.1 ± 0.6 |
| Death avoidance | -1.1 ± 1.8 | 0 ± 0.8 |
| Neutral acceptance | 0.2 ± 0.6 | 0.1 ± 0.6 |
| Approach acceptance | -0.1 ± 1.1 | 0.3 ± 0.7 |
| Escape acceptance | 0 ± 0.9 | 0.4 ± 1.0 |
The Self-Compassion Scale (SCS) is a 26-item self-reported questionnaire that assesses how respondents relate to themselves and treat themselves during difficult or painful experiences. Items are scored along a 5-point Likert-type scale ranging from 1 "almost never" to 5 "almost always." The SCS has six component (subscale) scores: self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification. Subscale scores are calculated by computing the mean of subscale item responses. A total self-compassion score is calculated by the sum of the subscale scores and range from 24 to 120 with higher scores indicating greater self compassion. Higher scores have been found to correlate with positive mental health outcomes, as well as decreased depression and anxiety.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy (125 mg) |
|---|---|---|
| Change in Self-Compassion Scale (SCS) From Baseline to Primary Endpoint | -0.04 ± 0.5 | 0.4 ± 0.7 |
Collected over Adverse events were collected throughout the study: up to 2 months after the 2nd experimental session (for Stage 1 blinded for placebo group), at the end of Stage 1 (for MDMA group), up to 2 months after the 3rd experimental session (for Stage 2 crossover group), and at 12-month study follow-up (approximately 1 year following the 3rd MDMA session [following Stage 1 for participants in the MDMA arm and following crossover to Stage 2 for the Stage 1 placebo group] .. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo With Therapy (Blinded) | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| MDMA-assisted Therapy (125 mg) (Blinded) | 0/13 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| Placebo Group Open-label Crossover to Unblinded MDMA-assisted Therapy (125 mg) | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| MDMA Group Open-label MDMA-assisted Therapy (125 mg) | 0/13 (0%) | 0/13 (0%) | 3/13 (23.1%) |
| Placebo With Therapy Group 12-month Follow-up | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| MDMA-assisted Therapy Group 12-month Follow-up | 1/13 (7.7%) | 3/13 (23.1%) | 3/13 (23.1%) |
| Event | Placebo With Therapy (Blinded) | MDMA-assisted Therapy (125 mg) (Blinded) | Placebo Group Open-label Crossover to Unblinded MDMA-assisted Therapy (125 mg) | MDMA Group Open-label MDMA-assisted Therapy (125 mg) | Placebo With Therapy Group 12-month Follow-up | MDMA-assisted Therapy Group 12-month Follow-up |
|---|---|---|---|---|---|---|
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/5 | 0/13 | 0/5 | 0/13 | 0/5 | 1/13 |
| Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/5 | 0/13 | 0/5 | 0/13 | 0/5 | 1/13 |
| Cerebrovascular accidentNervous system disorders | 0/5 | 0/13 | 0/5 | 0/13 | 0/5 | 1/13 |
| Spinal cord paralysisNervous system disorders | 0/5 | 0/13 | 0/5 | 0/13 | 0/5 | 1/13 |
| ChordomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/5 | 0/13 | 0/5 | 0/13 | 0/5 | 1/13 |
| MeningitisInfections and infestations | 0/5 | 0/13 | 0/5 | 0/13 | 0/5 | 1/13 |
| SepsisInfections and infestations | 0/5 | 0/13 | 0/5 | 0/13 | 0/5 | 1/13 |
| Event | Placebo With Therapy (Blinded) | MDMA-assisted Therapy (125 mg) (Blinded) | Placebo Group Open-label Crossover to Unblinded MDMA-assisted Therapy (125 mg) | MDMA Group Open-label MDMA-assisted Therapy (125 mg) | Placebo With Therapy Group 12-month Follow-up | MDMA-assisted Therapy Group 12-month Follow-up |
|---|---|---|---|---|---|---|
| InsomniaPsychiatric disorders | 1/5 | 4/13 | 2/5 | 2/13 | 1/5 | 0/13 |
| FatigueGeneral disorders | 0/5 | 3/13 | 0/5 | 0/13 | 0/5 | 0/13 |
| AnxietyPsychiatric disorders | 0/5 | 1/13 | 1/5 | 1/13 | 0/5 | 0/13 |
| Depressed moodPsychiatric disorders | 0/5 | 1/13 | 1/5 | 0/13 | 0/5 | 0/13 |
| DepressionPsychiatric disorders | 0/5 | 1/13 | 0/5 | 0/13 | 1/5 | 0/13 |
| PainGeneral disorders | 0/5 | 1/13 | 1/5 | 0/13 | 0/5 | 0/13 |
| UrticariaSkin and subcutaneous tissue disorders | 0/5 | 1/13 | 1/5 | 0/13 | 0/5 | 0/13 |
| Chest PainGeneral disorders | 1/5 | 0/13 | 0/5 | 0/13 | 0/5 | 0/13 |
| Muscle SpasmMusculoskeletal and connective tissue disorders | 1/5 | 0/13 | 0/5 | 0/13 | 0/5 | 0/13 |
| Neuropathy peripheralNervous system disorders | 1/5 | 0/13 | 1/5 | 0/13 | 1/5 | 0/13 |
Intent-to-treat (ITT) set
| Age, Continuous(years) | Placebo With Therapy | MDMA-assisted Therapy (125 mg) | Total |
|---|---|---|---|
| Mean | 53.2 ± 10.5 | 55.5 ± 7.0 | 54.9 ± 7.9 |
| Sex: Female, Male(Participants) | Placebo With Therapy | MDMA-assisted Therapy (125 mg) | Total |
|---|---|---|---|
| Female | 4 | 10 | 14 |
| Male | 1 | 3 | 4 |
| Race/Ethnicity, Customized(Participants) | Placebo With Therapy | MDMA-assisted Therapy (125 mg) | Total |
|---|---|---|---|
| Race — White/Caucasian | 3 | 12 | 15 |
| Race — Black/African American | 1 | 0 | 1 |
| Race — Other | 1 | 1 | 2 |
| Baseline State-Trait Anxiety Inventory Trait (STAI-T)(units on a scale) | Placebo With Therapy | MDMA-assisted Therapy (125 mg) | Total |
|---|---|---|---|
| Mean | 62.5 ± 7.31 | 57.4 ± 5.18 | 61.1 ± 7.03 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — We will share outcome data appearing in any published reports upon request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data and study-related documents will be available when all participants have completed the study, and when data has been quality checked and locked.
Access criteria: Interested persons should correspond with the central contact for the multisite study.
Ran from May 2015 to primary completion in Apr 2017, 23 months.
Results were first posted in Aug 2021, 4 years 3 months after primary completion. A results delay was requested in Jun 2020.
Of 96 phase 2 interventional studies under Anxiety Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 59. This study's 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine